Molecular analysis of mixed endometrial carcinomas shows clonality in most cases

American Journal of Surgical Pathology

Volumn 40, Issue 2, 2016, Pages 166-180

  Kobel, Martin ^a   Meng, Bo ^b   Hoang, Lien N ^c   Almadani, Noorah ^c   Li, Xiaodong ^b   Soslow, Robert A ^d   Blake Gilks, C ^c   Lee, Cheng Han ^b  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Endometrial cancer; Endometrioid carcinoma clear cell carcinoma; Mixed carcinoma; Nextgeneration sequencing; Serous carcinoma

Indexed keywords

TUMOR MARKER;

AGED; ALBERTA; CANCER GRADING; CARCINOMA; CHEMISTRY; CLINICAL TRIAL; CLONAL EVOLUTION; COMPARATIVE STUDY; DNA MUTATIONAL ANALYSIS; ENDOMETRIAL NEOPLASMS; FEMALE; GENETIC PREDISPOSITION; GENETICS; HIGH THROUGHPUT SEQUENCING; HUMAN; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MOLECULAR DIAGNOSIS; MOLECULAR EVOLUTION; MULTICENTER STUDY; MUTATION; NEOPLASMS, COMPLEX AND MIXED; PATHOLOGY; PHENOTYPE; PREDICTIVE VALUE; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALBERTA; BIOMARKERS, TUMOR; CARCINOMA; CLONAL EVOLUTION; DNA MUTATIONAL ANALYSIS; ENDOMETRIAL NEOPLASMS; EVOLUTION, MOLECULAR; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; NEOPLASM GRADING; NEOPLASMS, COMPLEX AND MIXED; PHENOTYPE; PREDICTIVE VALUE OF TESTS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84958036913     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000536     Document Type: Article

References (41)

1. Zaino RJ, Carinelli SG, Ellenson LH, et al. Tumours of the Uterine Corpus-Epithelial Tumours and Precursors World Health Organization Classification of Tumours of Female Reproductive Organs. Lyon, France: IARC Press; 2014:125-132.
2. Quddus MR, Sung CJ, Zhang C, et al. Minor serous and clear cell components adversely affect prognosis in"mixed-type" endometrial carcinomas: a clinicopathologic study of 36 stage-I cases. Reprod Sci. 2010;17:673-678.
3. Carcangiu ML, Chambers JT. Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma. Gynecol Oncol. 1992;47:298-305.
4. Sherman ME, Bitterman P, Rosenshein NB, et al. Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features. Am J Surg Pathol. 1992;16:600-610.
5. Williams KE, Waters ED, Woolas RP, et al. Mixed serous-endometrioid carcinoma of the uterus: pathologic and cytopatho-logic analysis of a high-risk endometrial carcinoma. Int J Gynecol Cancer. 1994;4:7-18.
6. Roelofsen T, van Ham MA, Wiersma van Tilburg JM, et al. Pure compared with mixed serous endometrial carcinoma: two different entities? Obstet Gynecol. 2012;120:1371-1381.
7. Alkushi A, Kobel M, Kalloger SE, et al. High-grade endometrial carcinoma: serous and grade 3 endometrioid carcinomas have different immunophenotypes and outcomes. Int J Gynecol Pathol. 2010;29:343-350.
8. Demopoulos RI, Mesia AF, Mittal K, et al. Immunohistochemical comparison of uterine papillary serous and papillary endometrioid carcinoma: clues to pathogenesis. Int J Gynecol Pathol. 1999;18: 233-237.
9. Yemelyanova A, Ji H, Shih IeM, et al. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endome-trioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Am J Surg Pathol. 2009;33:1504-1514.
10. Hoang LN, McConechy MK, Kobel M, et al. Histotype-genotype correlation in 36 high-grade endometrial carcinomas. Am J Surg Pathol. 2013;37:1421-1432.
11. Fadare O, Liang SX. Diagnostic utility of hepatocyte nuclear factor 1-beta immunoreactivity in endometrial carcinomas: lack of specificity for endometrial clear cell carcinoma. Appl Immunohis-tochem Mol Morphol. 2012;20:580-587.
12. Hoang LN, Han G, McConechy M, et al. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma-diagnostic utility of HNF-1beta and oestrogen receptor. Histopa-thology. 2014;64:585-596.
13. Yamamoto S, Tsuda H, Aida S, et al. Immunohistochemical detection of hepatocyte nuclear factor 1beta in ovarian and endometrial clear-cell adenocarcinomas and nonneoplastic endome-trium. Hum Pathol. 2007;38:1074-1080.
14. Hoang LN, McConechy MK, Meng B, et al. Targeted mutation analysis of endometrial clear cell carcinoma. Histopathology. 2015; 66:664-674.
15. Fadare O, Desouki MM, Gwin K, et al. Frequent expression of napsin A in clear cell carcinoma of the endometrium: potential diagnostic utility. Am J Surg Pathol. 2014;38:189-196.
16. Bartosch C, Manuel Lopes J, Oliva E. Endometrial carcinomas: a review emphasizing overlapping and distinctive morphological and immunohistochemical features. Adv Anat Pathol. 2011;18:415-437.
17. Clement PB, Young RH. Non-endometrioid carcinomas of the uterine corpus: a review of their pathology with emphasis on recent advances and problematic aspects. Adv Anat Pathol. 2004;11: 117-142.
18. Lim D, Ip PP, Cheung AN, et al. Immunohistochemical comparison of ovarian and uterine endometrioid carcinoma, endometrioid carcinoma with clear cell change, and clear cell carcinoma. Am J Surg Pathol. 2015;39:1061-1069.
19. Darvishian F, Hummer AJ, Thaler HT, et al. Serous endometrial cancers that mimic endometrioid adenocarcinomas: a clinicopatho-logic and immunohistochemical study of a group of problematic cases. Am J Surg Pathol. 2004;28:1568-1578.
20. Soslow RA. Endometrial carcinomas with ambiguous features. Semin Diagn Pathol. 2010;27:261-273.
21. Han G, Sidhu D, Duggan MA, et al. Reproducibility of histological cell type in high-grade endometrial carcinoma. Mod Pathol. 2013;26: 1594-1604.
22. Hoang LN, McConechy MK, Koebel M, et al. Histotype-genotype correlation in 36 high-grade endometrial carcinomas. Am J Surg Pathol. 2013;37:1421-1432.
23. Kobel M, Reuss A, Bois A, et al. The biological and clinical value of p53 expression in pelvic high-grade serous carcinomas. J Pathol. 2010;222:191-198.
24. Kandoth C, Schultz N, Cherniack AD, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67-73.
25. Kuhn E, Wu RC, Guan B, et al. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst. 2012;104:1503-1513.
26. Le Gallo M, O'Hara AJ, Rudd ML, et al. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet. 2012;44:1310-1315.
27. McConechy MK, Anglesio MS, Kalloger SE, et al. Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas. J Pathol. 2011;223:567-573.
28. McConechy MK, Ding J, Cheang MC, et al. Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol. 2012;228:20-30.
29. Zhao S, Choi M, Overton JD, et al. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci USA. 2013;110:2916-2921.
30. Talhouk A, McConechy M, Leung S, et al. A clinically applicable molecular-based classification of endometrial cancers. Br J Cancer. 2015;113:299-310.
31. Meng B, Hoang LN, McIntyre JB, et al. POLE exonuclease domain mutation predicts long progression-free survival in grade 3 endome-trioid carcinoma of the endometrium. Gynecol Oncol. 2014;134:15-19.
32. Church DN, Stelloo E, Nout RA, et al. Prognostic significance of POLE proofreading mutations in endometrial cancer. J Natl Cancer Inst. 2014;107:402.
33. McConechy MK, Talhouk A, Li-Chang HH, et al. Detection of DNA mismatch repair (MMR) deficiencies by immunohistochem-istry can effectively diagnose the microsatellite instability (MSI) phenotype in endometrial carcinomas. Gynecol Oncol. 2015;137: 306-310.
34. Pradhan M, Abeler VM, Davidson B, et al. DNA ploidy heterogeneity in endometrial carcinoma: comparison between curettage and hysterectomy specimens. Int J Gynecol Pathol. 2010; 29:572-578.
35. Hussein YR, Weigelt B, Levine DA, et al. Clinicopathological analysis of endometrial carcinomas harboring somatic POLE exonuclease domain mutations. Mod Pathol. 2015;28:505-514.
36. Nelson GS, Pink A, Lee S, et al. MMR deficiency is common in high-grade endometrioid carcinomas and is associated with an unfavorable outcome. Gynecol Oncol. 2013;131:309-314.
37. Allo G, Bernardini MQ, Wu RC, et al. ARID1A loss correlates with mismatch repair deficiency and intact p53 expression in high-grade endometrial carcinomas. Mod Pathol. 2014;27:255-261.
38. Burke JE, Perisic O, Masson GR, et al. Oncogenic mutations mimic and enhance dynamic events in the natural activation of phosphoi-nositide 3-kinase p110alpha (PIK3CA). Proc Natl Acad Sci USA. 2012;109:15259-15264.
39. Gymnopoulos M, Elsliger MA, Vogt PK. Rare cancer-specific mutations in PIK3CA show gain of function. Proc Natl Acad Sci USA. 2007;104:5569-5574.
40. Coenegrachts L, Garcia-Dios DA, Depreeuw J, et al. Mutation profile and clinical outcome of mixed endometrioid-serous endo-metrial carcinomas are different from that of pure endometrioid or serous carcinomas. Virchows Arch. 2015;466:415-422.
41. Stelloo E, Bosse T, Nout RA, et al. Refining prognosis and identifying targetable pathways for high-risk endometrial cancer; a Trans PORTEC initiative. Mod Pathol. 2015;28:836-844.